Lengsfeld, Sophia
Burkard, Thilo
Meienberg, Andrea
Jeanloz, Nica
Coynel, David
Vogt, Deborah R.
Hemkens, Lars G.
Speich, Benjamin
Zanchi, Davide
Erlanger, Tobias E.
Christ-Crain, Mirjam
Winzeler, Bettina http://orcid.org/0000-0001-8305-2700
Funding for this research was provided by:
The University Hospital Basel (and the integrated Clinical Trial Unit and Department of Endocrinology, Diabetology and Metabolism) provide the location and infrastructure.
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
goldschmidt&Jakobson Stiftung
University Hospital Basel, Pool Medizin im Jahr 2021
Gottfried und Julia Bangerter-Rhyner-Stiftung
Hemmi Foundation
Department of Internal Medicine of the University Hospital of Basel
Swiss Academy of Medical Sciences
Research Foundation of the University of Basel
University of Basel
Article History
Received: 30 January 2022
Accepted: 9 February 2023
First Online: 20 April 2023
Declarations
:
: The local ethics committee Ethikkommission beider Basel (Study Number BASEC 2017–00286) as well as the Swiss Agency for Therapeutic Products SWISSMEDIC (Reference Number 2017DR2066) approved the study protocol. Important protocol modifications are approved before initiating any changes and communicated to relevant parties. Written informed consent to participate is obtained from all participants, prior to randomization.
: No identifying images or other personal or clinical details of participants are presented here nor will be presented in reports of the trial results. Informed consent materials are available (Additional file InternalRef removed).
: The authors declare that they have no competing interests. LGH: The Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) is supported by the Foundation Clinical Neuroimmunology and Neuroscience Basel.